Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | OS Therapies Inc - 10-K, Annual Report | - | SEC Filings | ||
Mo | OS Therapies macht Fortschritte mit OST-HER2 für Osteosarkom | 1 | Investing.com Deutsch | ||
OS THERAPIES Aktie jetzt für 0€ handeln | |||||
Mo | OS Therapies advances OST-HER2 for osteosarcoma | 3 | Investing.com | ||
11.03. | OS Therapies, Inc.: OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma | 240 | Business Wire | OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific... ► Artikel lesen | |
28.02. | Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 311 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the... ► Artikel lesen | |
24.02. | OS Therapies sets up subsidiary to seek ADC joint ventures with US, China peers | 2 | FierceBiotech | ||
24.02. | OS Therapies gründet Tochtergesellschaft für Fortschritte bei Krebsmedikamenten | 1 | Investing.com Deutsch | ||
24.02. | OS Therapies creates subsidiary for cancer drug advances | 1 | Investing.com | ||
14.02. | Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer | 2 | Benzinga.com | ||
14.02. | OS Therapies bereitet sich auf FDA-Treffen zu Krebsmedikament vor | 2 | Investing.com Deutsch | ||
14.02. | OS Therapies gears up for FDA meeting on cancer drug | 1 | Investing.com | ||
04.02. | OS Therapies gears up for osteosarcoma drug approval | 1 | Investing.com | ||
04.02. | OS Therapies bereitet sich auf die Zulassung eines Osteosarkom-Medikaments vor | 1 | Investing.com Deutsch | ||
31.01. | OS Therapies announces offering of 10.83M shares by selling stockholders | 1 | Seeking Alpha | ||
31.01. | OS Therapies Inc - S-1, General form for registration of securities | - | SEC Filings | ||
29.01. | OS Therapies pays $8M for full IP rights to its lead drug, gains 2 more cancer assets in the process | 1 | FierceBiotech | ||
29.01. | OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up | - | RTTNews | ||
29.01. | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | 150 | Business Wire | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
29.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
15.01. | Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday? | 1 | Benzinga.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CRISPR THERAPEUTICS | 31,600 | +2,93 % | Crispr Therapeutics Aktie: Verliert ihren Kurs? | Der Austritt des operativen Geschäftsführers beim Gentherapie-Unternehmen beunruhigt Investoren und wirft Fragen zur Projektkontinuität im wettbewerbsintensiven Biotech-Sektor auf. Die Finanzmärkte... ► Artikel lesen | |
IMMUNIC | 0,990 | +0,25 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 1,260 | -0,79 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update | Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - March 31, 2025)... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 10,090 | +7,00 % | Arcturus Therapeutics Holdings Aktie: Rückschritt voraus? | Biotechnologieunternehmen meldet positive Entwicklungen bei Studien zu Mukoviszidose und OTC-Mangel während die Aktie einen erheblichen Wertverlust verzeichnet Arcturus Therapeutics Holdings Inc. (ARCT)... ► Artikel lesen | |
PROTALIX BIOTHERAPEUTICS | 2,338 | +0,39 % | Amended: Protalix Annual Earnings Fall | JERUSALEM (dpa-AFX) - (Amended: Recasting the story to correct the period, revenue)Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday reported a decline in earnings for... ► Artikel lesen | |
SCILEX | 0,305 | +33,10 % | Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva | PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing... ► Artikel lesen | |
CHECKPOINT THERAPEUTICS | 3,690 | -1,60 % | Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates | WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial... ► Artikel lesen | |
MEIRAGTX | 5,900 | +2,61 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
INVIVYD | 0,571 | +3,84 % | Invivyd adds venture capitalist Ajay Royan to board | ||
UNICYCIVE THERAPEUTICS | 0,561 | +3,18 % | Unicycive Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
QIAGEN | 36,910 | -0,61 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
EVOTEC | 5,905 | -3,59 % | Evotec-Aktie: Crash auf 4 Euro voraus? Behält die Deutsche Bank Recht mit Ihrem Kursziel? | © Foto: Symbolbild von pina messina auf UnsplashKooperationen mit Pharma-Giganten, Hightech-Forschung und trotzdem bewegt sich die Evotec-Aktie nicht richtig nach oben. Die Deutsche Bank warnte vor... ► Artikel lesen | |
BIONTECH | 85,20 | +0,35 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Biontech auf "Buy" mit einem Kursziel von 140 US-Dollar belassen. Analyst Emmanuel Papadakis befasste sich in einer am Mittwoch... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,020 | -25,38 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
BB BIOTECH | 31,350 | -1,72 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen |